"Following the end of this quarter, we plan to finalize the financing, complete the previously announced acquisitions of Pantheon Medical and MediSource Partners, followed by Fuse Medical in all-stock transactions, file an S1 Registration statement with the SEC, and file a request for up-list to a national exchange. It is also important to point out that the Fuse Medical acquisition will provide Generex with a public vehicle for the spin-out of our wholly-owned subsidiary NuGenerex Immuno-Oncology (previously Antigen Express)"

Light at the end of the tunnel but the end of the tunnel is still a ways off.